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Aim: To evaluate Medicaid spending and healthcare resource utilization (HRU) in treatment-resistant de-
pression (TRD). Materials & methods: TRD beneficiaries were identified from Medicaid claims databases
(January 2010–March 2017) and matched 1:1 with major depressive disorder (MDD) beneficiaries without
TRD (non-TRD-MDD) and randomly selected patients without MDD (non-MDD). Differences in HRU and
per-patient-per-year costs were reported in incidence rate ratios (IRRs) and cost differences (CDs), respec-
tively. Results: TRD beneficiaries had higher HRU than 1:1 matched non-TRD-MDD (e.g., inpatient visits:
IRR = 1.41) and non-MDD beneficiaries (N = 14,710 per cohort; e.g., inpatient visits: IRR = 3.42, p < 0.01).
TRD beneficiaries incurred greater costs versus non-TRD-MDD (CD = US$4382) and non-MDD beneficiaries
(CD = US$8294; p < 0.05). Conclusion: TRD is associated with higher HRU and costs versus non-TRD-MDD
and non-MDD. TRD poses a significant burden to Medicaid.
First draft submitted: 3 December 2018; Accepted for publication: 22 January 2019; Published online:
8 February 2019
Keywords: burden of illness • healthcare costs • healthcare resource utilization • major depressive disorder • Medi-
caid • treatment-resistant depression
Major depressive disorder (MDD) is estimated to affect 15.4 million people in the USA, representing nearly 6.7%
of the total population [1]. In 2015, the societal cost burden of people with MDD was quantified at US$210.5
billion, highlighting the substantial economic burden of this condition [2]. While antidepressants can effectively
treat MDD, approximately half of pharmacologically treated MDD patients do not respond to an adequate trial of
an antidepressant medication, and a significant proportion of these patients do not respond to subsequent lines of
pharmacotherapy [3]. Failure to respond adequately to at least two antidepressant treatments of adequate dose and
duration is often referred to as treatment-resistant depression (TRD), although a universally accepted definition is
lacking [4].
Mental illness disproportionately affects disadvantaged populations of lower socioeconomic status [5]. Medicaid is
a US federal program that, jointly with the Children’s Health Insurance Program, provides basic health insurance to
over 72.5 million Americans with a low income [6]. Eligibility groups made mandatory across all states include low-
income families, qualified pregnant women and children, and citizens receiving supplemental security income [6].
As of 2015, approximately 9.1 million low-income adult Medicaid beneficiaries had mental illness, and 2.5 million
reported an unmet need for mental health treatment [7]. Moreover, although accounting for approximately 20%
of the population, patients with behavioral health conditions account for 48% of Medicaid spending [7]. In the
USA, it is estimated that almost a third of low-incomeMedicaid beneficiaries have been diagnosed with depression,
representing twice the rate of the nation [8,9]. With most research efforts to date focusing on commercially insured
patients, there is a need to assess the burden of TRD among low-income Medicaid beneficiaries [10–12]. The wealth
of data that can be extracted from Medicaid, the largest single source of financing for mental health services in the
USA [8], makes it a particularly suitable data source to address this research question.
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This retrospective cohort study was conducted to assess the cost and healthcare resource utilization (HRU)
burden of TRD in Medicaid beneficiaries using a design similar to that of a commercial analysis performed by
Amos et al. [10], allowing indirect comparisons to be made between both studies. Our study also aimed to assess the
robustness and replicability of results recently published in a Medicaid-insured population [13]. To our knowledge,
no other study has been conducted to date.
Methods
Data source
This study was conducted using Medicaid healthcare claims databases, which included the states of Iowa, Missouri,
Mississippi, Kansas, New Jersey andWisconsin. Data were available from 1 July 2009 through 31March 2017 for all
states except New Jersey and Wisconsin, for which data were available through 31 March 2014 and 31 December
2013, respectively. The Medicaid databases contain medical and drug claims data representing approximately
26.6 million Medicaid eligible persons. Information on medical claims (e.g., payment and days of supplied data
by provider, and date of service; International Classification of Diseases, 9th revision [ICD-9-CM] diagnoses;
International Classification of Diseases, 10th revision [ICD-10-CM] diagnoses; Current Procedural Terminology
codes), prescription drug claims and eligibility (e.g., age, gender, and enrollment start and end dates) were also
available. All data were compliant with the Health Insurance Portability and Accountability Act, and thus no ethical
review was necessary.
Study design & cohorts
The study used a retrospective longitudinal-matched cohort design where beneficiaries with TRD were compared
with two control cohorts: beneficiaries with MDD who did not have TRD (non-TRD MDD cohort) and
beneficiaries without MDD (non-MDD cohort).
The TRD and non-TRDMDD cohorts consisted of adult (i.e., ≥18 years of age) patients who had greater than
or equal to one diagnosis for MDD (ICD-9-CM: 296., ICD-10-CM: F32.x [excluding F32.8]; F33.x, [excluding
F33.8]; see Supplementary Table 1 for the code definitions) between 1 July 2009 and 31 March 2017; had greater
than or equal to one claim for an antidepressant starting from January 2010 (defined as the index date) without
antidepressant claims 6 months before (defined as the baseline period); had greater than or equal to one diagnosis
for depression (ICD-9-CM: 296.2x, 296.3x, 300.4x, 311.x, 309.0x or 309.1x; ICD-10-CM: F32.x, F33.x, F34.1
or F43.21; see Supplementary Table 1 for the code definitions) during the baseline or observation period; and had
claims for greater than or equal to one antidepressant agent with an adequate dose and duration on or after the
index date. Adequate dose was defined as the minimum starting dose recommended by the American Psychiatric
Association treatment guidelines [14]. Adequate duration was defined as ≥6 weeks of continuous therapy with no
gaps longer than 14 days.
MDD patients were classified in the TRD cohort if they received two antidepressant treatment courses (i.e., aug-
mentation therapy with anticonvulsant, anxiolytic, antipsychotic, lithium, psychostimulant and thyroid hormone
medications) with adequate dose and duration during the observation period and then initiated a third, with the
assumption that patients doing well on a treatment course would not progress to another line of therapy. Failure of
a treatment course was defined as a switch of antidepressant (<180 days after the end of the previous treatment),
the addition of an antidepressant or the initiation of an augmentation therapy. Beneficiaries with MDD who did
not meet the above criteria for TRD were classified in the non-TRD MDD cohort.
A total of 1,000,000 adult patients without an MDD diagnosis at any time during the study period were
randomly selected and subsequently assessed for study eligibility. The index date was randomly assigned during 1
January 2010–31 March 2017.
For each study cohort, patients were excluded from the study if they met any of the following criteria: diagnoses
for specific psychiatric comorbidities (i.e., psychosis [ICD-9-CM: 298.xx; ICD-10-CM: F23.x, F25.x, F44.89],
schizophrenia [ICD-9-CM: 295.xx; ICD-10-CM: F20.x, F25.x], bipolar disorder/manic depression [ICD-9-CM:
296.0x, 296.1x, 296.4x, 296.5x, 296.6x, 296.7x, 296.8x; ICD-10-CM: F30.x, F31.x] or dementia [ICD-9-CM:
290.xx, 294.1x; ICD-10-CM: F01.x, F02.x, F03.x]; see Supplementary Table 1 for the code definitions) between
1 July 2009–31 March 2017; and <6 months of continuous eligibility pre- and post-index date.
Baseline characteristics were evaluated during the baseline period. Study outcomes were evaluated from the index
date up until the earliest among 2 years postindex, end of continuous eligibility or end of data availability (i.e., the
observation period).
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Study outcomes
Study outcomes included antidepressant treatment patterns, HRU and costs. Antidepressant treatments com-
prised selective serotonin reuptake inhibitors (SSRIs), norepinephrine–dopamine reuptake inhibitors (NDRIs),
serotonin–norepinephrine reuptake inhibitors (SNRIs), serotonin modulators (i.e., nefazodone, trazodone, vi-
lazodone, venlafaxine), tricyclics and tetracyclics, norepinephrine–serotonin modulators, monoamine oxidase in-
hibitors and others (i.e., olanzapine–fluoxetine). The proportion of patients using antidepressant medication during
the observation period was reported for each cohort.
HRU and cost outcomes were stratified into all-cause, behavioral health (including depression) and depression-
related. For each stratum, the following categories were evaluated: inpatient visits, inpatient days, emergency
department visits, outpatient visits, home care, mental-health institute admissions, long-term care admissions and
other visits.
Behavioral health medical HRU and costs were identified using the following primary or secondary ICD-9-
CM diagnostic codes: 290.xx-319. xx, and ICD-10-CM diagnostic codes: F01.xxx-F99.xxx; see Supplementary
Table 1 for the code definitions. Depression-related medical costs were identified using the following primary or
secondary ICD-9-CM diagnostic codes: 296.2x, 296.3x, 300.4x, 309.0x, 309.1x, 311. xx and ICD-10-CM: F32.x,
F33.x, F34.1 or F43.21; see Supplementary Table 1 for the code definitions. Behavioral health pharmacy costs
included anxiolytics, anticonvulsants/mood stabilizers, antipsychotics, antidepressants and other mood stabilizers
(e.g., lithium). Depression-related pharmacy costs included SSRIs, NDRIs, SNRIs, serotonin modulators, tricyclics
and tetracyclics, norepinephrine–serotonin modulators, monoamine oxidase inhibitors and olanzapine–fluoxetine.
Statistical analysis
To control for potential confounding, control cohorts (i.e., the non-TRD MDD and non-MDD cohorts) were
matched 1:1 to the TRD cohort based on demographic characteristics using exact matching factor (i.e., state) and
propensity scores (PS). The PS was defined as the conditional probability of having TRD based on observable
characteristics, and was estimated from a logistic regression model, in which belonging to the TRD cohort
(yes/no) was the binary-dependent variable, and patient characteristics were predictors. PS were modeled using
multivariate logistic regression controlling for age, sex, year of the index date, dual eligibility coverage (i.e., dual
Medicaid/Medicare coverage) and Medicaid health managed care organization coverage. Differences in baseline
characteristics before and aftermatchingwere compared using standardized differences, with an acceptance threshold
of ≤10% [15–17]. Rates of HRU were compared using multivariate negative binomial regression and reported using
incidence rate ratios. Costs were expressed per patient per year (PPPY; 2016 US$), and adjusted cost differences
were calculated using multivariate ordinary least squares regression, with the TRD cohort serving as reference
for those calculations. Multivariate models were adjusted for baseline total healthcare costs and Quan–Charlson
comorbidity index. Cost differences, CIs and p-values were obtained from a nonparametric bootstrap procedure
(499 replications). Continuous variables were reported using means, standard deviations and medians; categorical
variables were reported using frequencies and percentages.
Unadjusted all-cause healthcare costs were also compared as part of a sensitivity analysis.
Results
Demographic & clinical characteristics
Among 54,405 beneficiaries with MDD who received treatment of adequate dose and duration, 14,170 (26.1%)
met the criteria to be classified in the TRD cohort, and 40,235 were classified in the non-TRD MDD cohort. A
total of 223,799 patients were included in the non-MDD cohort. Patients in the TRD cohort had an average age
of 42.5 years (standard deviation: 12.3) and were primarily female (73.4%; Supplementary Table 2).
Matched control cohorts (N = 14,170 in each cohort) were generally well balanced to theTRDcohort with respect
to demographic characteristics (Supplementary Table 2). The all-cause medical (US$12,673 [TRD] vs US$11,732
[non-TRD MDD] PPPY) and all-cause pharmacy (US$1290 [TRD] vs US$1374 [non-TRD MDD] PPPY)
costs during the baseline period were balanced between the TRD and non-TRD MDD cohorts (all standardized
difference <10%). With respect to clinical characteristics, the matched TRD and non-TRD MDD cohorts were
well balanced for all evaluated characteristics except other mental health diagnoses medication use (38.1% [TRD]
vs 29.9% [non-TRD MDD]). Demographic characteristics were generally well balanced between the TRD and
non-MDD cohorts as well. The mean durations of the observation period were 21.8, 20.6 and 17.8 months in the
TRD, non-TRD MDD and the non-MDD cohort, respectively.
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Figure 1. Medication treatment patterns during the observation period of patients in the treatment-resistant depression,
non-treatment-resistant depression major depressive disorder and non-major depressive disorder cohorts in the USA (1 January 2010–31
March 2017).
†The small proportions of patients in the nonmajor depressive disorder cohort who had claims for antidepressants may reflect use of
antidepressants for approved indications other than major depressive disorder, or off-label use.
‡Serotonin modulators included the following individual agents: nefazodone, trazodone, vilazodone and vortioxetine.
*p < 0.05 (comparator: treatment-resistant depression cohort).
MAOI: Monoamine oxidase inhibitor; MDD: Major depressive disorder; NDRI: Norepinephrine–dopamine reuptake inhibitor; SNRI:
Serotonin-norepinephrine reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor; TRD: Treatment-resistant depression.
Treatment patterns
The antidepressant classes most commonly used were SSRIs (84.8 vs 77.6%; order hereinafter representing TRD
vs non-TRD MDD, respectively), serotonin modulators (50.0 vs 22.3%), SNRIs (49.6 vs 24.6%), NDRIs (34.4
vs 16.8%) and tricyclics/tetracyclics (31.4 vs 12.3%; Figure 1). The same top five classes were found for patients
in the non-MDD cohort, but utilization rates were much lower (Figure 1).
HRU outcomes
With respect to all-causeHRU, beneficiaries with TRDhad significantly higher rates of all evaluatedHRU categories
during the observation period compared with either the non-TRDMDD or non-MDD cohort (e.g., 1.4- and 3.4-
times the rate of inpatient visits vs beneficiaries with non-TRD MDD and non-MDD, respectively; all p < 0.01;
Figure 2). With respect to behavioral health- and depression-related HRU, the same trends were observed: Relative
to the non-TRD MDD and non-MDD cohorts, beneficiaries with TRD had higher rates of behavioral-health
HRU (e.g., 1.9- and 10.9-times the rate of inpatient visits, respectively; all p < 0.01; Supplementary Table 3)
and depression-related HRU (e.g. 1.7-times the rate of inpatient visits vs beneficiaries with non-TRD MDD; p
< 0.01; Supplementary Table 3). Of the eight all-cause HRU categories evaluated (i.e., inpatient visits, number of
inpatient days, emergency department visits, outpatient visits, home care visits, mental-health institute admissions,
long-term care admissions and other visits), all except the other visits category had rates increased by >20% in the
TRD versus non-TRDMDD comparison, and all but home care visits and other visits had rates increased by more
than twofold in the TRD versus non-MDD comparison (Figure 2).
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Figure 2. All-cause healthcare resource utilization measured from the index date up to 2 years postindex date in the USA (1 January
2010–31 March 2017).
†Incidence rate ratios, 95% CIs and p-values were estimated using multivariate (adjusting for baseline total healthcare cost and
Quan–Charlson comorbidity index) generalized linear model with a negative binomial distribution.
‡An incidence rate ratio greater than one indicates that the TRD cohort had higher adjusted rate of healthcare resource utilization than
control cohorts.
§Any visit not previously classified as a hospitalization, outpatient visit, emergency visit, long-term care, home visit or mental institute
visit.
*p < 0.05.
ED: Emergency department; HRU: Healthcare resource utilization; IRR: Incidence rate ratio; MDD: Major depressive disorder; TRD:
Treatment-resistant depression.
Cost outcomes
With respect to costs, patients with TRD, non-TRD MDD and non-MDD incurred a total of US$16,654,
US$12,133 and US$5812 in all-cause costs PPPY, respectively (Table 1 & Figure 3). Across all three study cohorts,
medical costs accounted for the majority of total costs (TRD = US$12,403 [74.5%], non-TRDMDD = US$9520
[78.5%], non-MDD = US$4662 [80.2%]). After adjusting for baseline healthcare costs and Quan-Charlson
comorbidity index, TRD beneficiaries incurred US$4382 and US$8294 higher PPPY total costs than non-TRD
MDD and non-MDD beneficiaries, respectively (all p < 0.01; Figure 3). This difference appeared largely driven
by higher medical costs (e.g., US$2767 higher PPPY costs vs non-TRD MDD, p < 0.01) and, to a lesser extent,
by higher pharmacy costs (e.g., US$1616 higher PPPY costs vs non-TRD MDD, p < 0.01; Table 1). When using
the non-MDD cohort as a comparator, the adjusted differences in medical and pharmacy costs reached US$5736
and US$2558, respectively (all p < 0.01; Table 1).
Behavioral-health costs accounted for US$2861 (17.2%) of total PPPY costs in the TRD cohort; US$1644
(13.5%) of total PPPY costs in the non-TRD MDD cohort; and US$495 (8.5%) of total PPPY costs in the non-
MDD cohort (Supplementary Table 4). Similarly, depression-related costs accounted for US$1224 (7.3%) of total
PPPY costs in the TRD cohort; US$696 (5.7%) of total PPPY costs in the non-TRD MDD cohort; and US$59
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Table 1. Direct healthcare costs by type of visit, measured from the index date up to 2 years postindex date (1 January
2010–31 March 2017).
Healthcare costs (US$2016)
per patient per year
Mean ± SD (median) Adjusted cost difference†,‡ (95% CI)
TRD cohort Non-TRD MDD
cohort
Non-MDD cohort Non-TRD MDD
cohort
p-value Non-MDD cohort p-value
All-cause costs
Total costs 16,654 ± 25,388
(10,170)
12,133 ± 22,212
(5985)
5812 ± 18826 (415) 4382 (3878; 4886)  0.001* 8294 (7755; 8851)  0.001*
Pharmacy costs 4251 ± 9876 (1814) 2612 ± 8659 (637) 1150 ± 5755 (3) 1616 (1414; 1819)  0.001* 2558 (2355; 2775)  0.001*
Medical costs 12,403 ± 21,130
(6700)
9520 ± 18,832
(4383)
4662 ± 17,099 (133) 2767 (2335; 3188)  0.001* 5736 (5289; 6204)  0.001*
– Inpatient costs 3688 ± 13128 (0) 2773 ± 12,248 (0) 1023 ± 8770 (0) 866 (588; 1130)  0.001* 1928 (1,661; 2,204)  0.00*
– ED costs 259 ± 655 (45) 191 ± 678 (4) 61 ± 603 (0) 67 (50; 82)  0.001* 185 (168; 199)  0.001*
– Outpatient costs 4126 ± 6717 (2275) 2813 ± 5052 (1289) 964 ± 4886 (0) 1299 (1170; 1430)  0.001* 2840 (2,699; 2,975)  0.001*
– Home care costs 1196 ± 5510 (0) 1038 ± 5639 (0) 809 ± 6440 (0) 140 (16; 261) 0.024* 8 (-142; 158) 0.890
– Mental-health institute costs 220 ± 1322 (0) 110 ± 837 (0) 10 ± 462 (0) 111 (81; 136)  0.001* 208 (182; 232)  0.001*
– Long-term care cost 599 ± 8089 (0) 521 ± 6497 (0) 226 ± 5030 (0) 57 (-106; 226) 0.537 50 (-118; 186) 0.557
– Other costs 2314 ± 4702 (581) 2075 ± 5635 (410) 1568 ± 7848 (0) 227 (117; 341)  0.001* 518 (341; 693)  0.001*
†Adjusted (total baseline healthcare cost and Charlson comorbidity index) cost differences were estimated using an ordinary least squares regression model and 95% CIs, and p-values
were estimated using a non-parametric bootstrap procedure (N = 499).
‡A cost difference greater than zero indicates that the TRD cohort had higher costs than non-TRD MDD control cohorts.
*p  0.05.
ED: Emergency department; MDD: Major depressive disorder; SD: Standard deviation; TRD: Treatment-resistant depression.
(1.0%) of total PPPY costs in the non-MDD cohort (Supplementary Table 4). However, when compared with the
non-TRDMDDcohort, patients in theTRDcohort incurredUS$1204 higher behavioral-health costs, representing
27.3% of the difference in all-cause costs (Supplementary Table 4). This difference reached US$2227 PPPY (26.9%
of the all-cause cost difference) when using the non-MDD cohort as the comparator group (Supplementary Table
4). In proportion, the incremental increase in pharmacy costs for TRD versus non-TRD MDD was higher than
that of medical costs during the observation period (e.g., 62.7% increase in pharmacy costs and 30.3% increase in
medical costs vs non-TRD MDD).
When comparing unadjusted costs as part of a sensitivity analysis, the all-cause costs PPPY for the demo-
graphically matched TRD cohort were not substantially different from the adjusted costs described above, with
cost differences reaching US$4521 and US$10,842 compared with the non-TRD MDD cohort and non-MDD
cohorts, respectively (all p < 0.01).
Discussion
In this retrospective study of Medicaid beneficiaries, the cost and HRU burden of TRD was assessed and compared
with two matched cohorts: one comprising patients with MDD who were not treatment resistant (i.e., the non-
TRDMDD cohort), and one comprising patients without MDD (i.e., the non-MDD cohort). Approximately one
out of four MDD patients met the study definition of TRD, a proportion seemingly higher than those previously
reported in other real-world studies [10,18–21]. Patients with TRD had at least 20% higher rates of all-cause HRU
across most HRU dimensions compared with matched patients with non-TRD MDD, highlighting the unmet
needs of patients with TRD and the high healthcare burden of this condition. The all-cause healthcare costs of
patients with TRD PPPY were US$4382 and US$8294 higher than those of patients with non-TRD MDD and
non-MDD, respectively. This suggests the need for new effective therapeutic strategies aiming to improve the
outcomes of TRD patients, which may translate into improved outcomes. Overall, these results support the high
prevalence and high cost burden of TRD among Medicaid beneficiaries and establish the robustness of the cost
and HRU estimates recently reported by Olfson et al. for a TRD Medicaid population [13].
The current study allows for the evaluation of the replicability and robustness of findings reported by Olfson
et al., who evaluated the cost and HRU burden in a Medicaid population [13]. In spite of some differences in study
design – including the stratification of the 2-year follow-up period as two consecutive 1-year periods (as done by
Olfson et al.), and the use of a matching procedure (as done here) – the cost and HRU estimates provided in
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the present study are largely consistent with those of Olfson et al. [13]. Perhaps the most striking similarity is the
prevalence of TRD, which Olfson et al. also estimated at 26% [13]. Furthermore, the results presented here build on
those of Olfson et al. by additionally describing the treatment patterns in this population and by providing relative
cost and HRU differences of TRD using patients without MDD as comparator. Another noteworthy difference is
that the Medicaid claims data used by Olfson et al. did not allow the population’s state of residency to be described,
an element that may be particularly relevant in light of geographical disparities in the application of the Medicaid
expansion.
Although the burden of TRD in a Medicaid population has been assessed, the putative incremental burden
of TRD in a Medicaid population versus a commercial population remained unclear due to the use of different
analytical methods and study designs among previous publications [10,13,19–21]. The present study used a nearly
identical design to Amos et al. [10], who assessed the burden of TRD in a commercially insured population. Because
of the similarity in design between this study and Amos et al.’s study, indirect comparisons of the burden of TRD
in commercially insured employed patients with Medicaid patients were possible.
When comparing antidepressant treatment patterns of TRDpatients with those observed by Amos et al. [10], three
antidepressant categories appeared to be used differently in both populations: serotonin modulators (i.e., Amos
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et al.: 39.8%, current study: 50.0%) and tricyclics/tetracyclics (i.e., Amos et al.: 17.5%, current study: 31.4%) were
more commonly used in the present Medicaid population, whereas NDRIs (i.e., Amos et al.: 52.6%, current study:
34.4%) were more commonly used in the population analysis by Amos et al. Since there appears to be only modest
differences in the efficacy of the different antidepressants currently available (within and between classes) [14], much
of these differences in treatment patterns are likely driven by physicians’ judgment of the impact of side effects
on these two populations (although other factors, such as patients’ preference, may also contribute). For example,
tricyclics may be particularly effective in hospitalized patients with more severe depression [14], which may explain
its use being more common in the Medicaid population since the proportion of Medicaid patients with a baseline
inpatient visit was almost twice as high as that observed in a commercial population [10]. Bupropion, an NDRI,
is associated with limited weight gain or even weight loss, making it a valuable treatment option for overweight
or obese patients [14]. The greater use of bupropion among commercially insured patients may reflect different
priorities of patients with commercial insurance versus Medicaid, or the clinician’s assumption of different priorities
among commercially insured patients.
Socioeconomic status is a well-known predictor of the risk of mental illness [5], and sociodemographic variables
like higher educational attainment and residence in middle- to high-income census tracts are associated with
better responses to antidepressants and remission, respectively [22,23]. While previous real-world estimates of the
prevalence of TRD among patients with MDD ranged between approximately 10–15% [18–21], the current study
reported a seemingly high proportion of 26%, which may well reflect these differences in socioeconomic status,
while Amos et al.’s study reported a proportion of 16% [10]. This supports the view that effective therapeutic
strategies aiming to overcome treatment resistance may be particularly important in low-income populations
like Medicaid beneficiaries. One of the most important limitations of currently available antidepressants is that
patients may only notice clinically meaningful improvements in their condition several weeks after initiating
treatment [24]. This delayed onset of action can negatively impact patients’ attitudes toward treatment and, in
turn, medication adherence [24]. Given the known association between lower economic status and adherence to
antidepressants [25,26], this limitation may be particularly important among Medicaid beneficiaries, hence the need
for more rapidly effective treatments in this population.
The observed total all-cause costs of each cohort, and cost differences between study cohorts, appeared largely
similar to those reported by Amos et al. [10], albeit the non-TRD MDD cohort having seemingly higher costs in
the current study (i.e., mean costs PPPY: Amos et al. = US$10,161 [2016]; current study = US$12,133 [2016],
note that costs in Amos et al. were inflated to 2016 USD using the US Medical Care consumer price index from
the Bureau of Labor Statistics from the US Department of Labor) [10]. Interestingly, despite the TRD population
having lower total all-cause costs in the current study versus Amos et al. [10], pharmacy costs were 18% higher in the
current study (i.e., Amos et al.: US$3597 [2016], current study: US$4251 [2016]). With respect to pharmacy costs,
this difference may be driven by the use of higher doses of antidepressants and differences in treatment patterns
discussed above, as well as differences in the use of other medications not related to mental health. However, it
should be noted that Medicaid rebates were not accounted for in the analyses performed here, which may lead to an
overestimation of the real proportion of pharmacy costs. In the USA, drug manufacturers are compelled to apply
a rebate in exchange for Medicaid coverage of their product. These rebates are not paid directly to Medicaid, but
are shared between the states and federal government, hence their presence not being accounted for in the current
analyses. With respect to the difference in total costs, this may be driven by lower reimbursements of medical care
by Medicaid. In fact, even though the Medicaid population had more inpatient visits (i.e., Amos et al.: 0.74 PPPY,
current study: 0.38 PPPY), inpatient costs were nonetheless lower in the Medicaid population (i.e., Amos et al.:
US$4644 [2016], current study: US$3688).
For each cohort, the majority of total costs were not behavioral health-related, and, thus, cost differences between
study cohorts were mostly driven by other types of healthcare expenditures. This is consistent with Amos et al.’s
study, which showed that behavioral health costs accounted for a minority of total costs among TRD and non-TRD
MDD patients [10], and also with another real-world study that focused on MDD as a whole (i.e., no stratification
for TRD) [2]. This result adds up to the view that comorbid conditions may account for substantial economic
burden of TRD [10] andMDD [2]. Of note, some studies suggested that comorbid physical illness may be associated
with poorer response to treatment [27–29], although others failed to see any difference [30–33]. Moreover, it has
been reported that individuals with severe mental illness are at an increased risk for a large number of physical
comorbidities [34], and that they are more likely to report difficulties in accessing care to get their medical needs
met [35].
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The current study is subject to limitations. First, the algorithm used to identify TRD patients relied on pharmacy
claims and could not incorporate other clinical considerations to specifically assess treatment failure, response and
remission. Second, the study population may not be representative of all patients with TRD or MDD. For
example, including patients who received an adequate dose and duration of antidepressant may have favored the
inclusion of adherent patients. Moreover, patients with depression may also have other psychiatric comorbidities,
but patients with concurrent diagnoses for psychosis, bipolar, manic disorder, schizophrenia or dementia were
excluded to ensure the index antidepressant was prescribed for depression. Third, patients in the non-MDD cohort
had a shorter follow-up compared with both MDD cohorts, and reasons for this difference could not be assessed.
However, study outcomes were reported on a PPPY basis to account for the differential lengths of follow-up between
cohorts. Fourth, as with all observational studies, these comparisons may be subject to residual confounding due to
unmeasured confounders. Finally, this analysis focused on beneficiaries using a six-state Medicaid claims database,
and therefore, findings may not be generalizable to the whole TRD population.
Conclusion
In this study of Medicaid beneficiaries, patients with TRD were observed to have higher HRU and costs compared
with non-TRD MDD and non-MDD beneficiaries, which is in-line with literature describing the burden of
TRD [13,19–21]. TRD poses a significant cost and HRU burden to Medicaid, which was mainly driven by nonbe-
havioral health HRU and costs, further demonstrating the need for developing effective treatments and patient
management strategies beyond those currently available.
Summary points
• Recent findings in a privately-insured population have shown that treatment-resistant depression (TRD) poses a
substantial burden to healthcare payers.
• Thus, this study was conducted to evaluate Medicaid spending and healthcare resource utilization (HRU) in
beneficiaries with TRD.
• A retrospective longitudinal matched-cohort study was conducted using multistate Medicaid claims databases to
identify adults diagnosed with major depressive disorder (MDD) between January 2010–March 2017, with the
date of the first antidepressant defined as the index date.
• MDD patients were considered to have TRD (i.e., the TRD cohort) after failing more than or equal to two
antidepressant treatment regimens (including augmentation therapy) at adequate dose and duration, and
initiating a third one. TRD beneficiaries were matched 1:1 to MDD beneficiaries without TRD (i.e., the non-TRD
MDD cohort) and a randomly selected group of beneficiaries without MDD (i.e., the non-MDD cohort). HRU and
cost outcomes were measured up to 2 years post-index date.
• Per-patient-per-year costs and HRU (in incidence rate ratios [IRRs]) were compared, respectively, using ordinary
least squares (p-value obtained using a nonparametric bootstrap) and negative binomial regressions.
• In total, 54,405 beneficiaries with MDD – including 14,710 (26.0%) TRD patients, 40,235 (74.0%) non-TRD MDD
patients – and 223,799 non-MDD patients were identified. TRD beneficiaries had higher rates of HRU than
non-TRD MDD (e.g., inpatient visits: IRR [95% CI] = 1.41 [1.35–1.47]; emergency department visits: IRR [95%
CI] = 1.31 [1.27–1.35]) and non-MDD cohorts (inpatient visits: IRR [95% CI] = 3.42 [3.31–3.54]; emergency
department visits: IRR [95% CI] = 3.57 [3.50–3.64]).
• Furthermore, TRD beneficiaries incurred significantly greater per-patient-per-year all-cause healthcare costs
relative to non-TRD MDD beneficiaries (US$16,654 vs US$12,133, adjusted cost difference: US$4382; p < 0.05) and
relative to non-MDD beneficiaries (US$16,654 vs US$5812, adjusted cost difference: US$8294; p < 0.05).
• Medicaid beneficiaries with TRD had higher HRU and costs compared with non-TRD MDD and non-MDD
beneficiaries. TRD poses a significant economic and HRU burden to Medicaid, further demonstrating the need for
developing effective treatments and patient management strategies beyond those currently available for
patients with MDD.
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